Inclusion Criteria:

- Histologically confirmed endometrial cancer, locally advanced, recurrent or
metastatic

- Karnofsky performance status (KPS) ≥ 70

- Measurable or non-measurable disease that has progressed since last treatment

- Receipt of prior platinum based chemotherapy regimen for advanced endometrial cancer

- Subjects may have received 2 prior chemotherapy (ie. cytotoxic) regimens if 1 regimen
was given for Stage I or II disease

- Women, ages 18 to older

Exclusion Criteria:

- Carcinosarcoma (malignant mixed mullerian tumor), endometrial leiomyosarcoma and
endometrial stromal sarcomas

- No prior first-line chemotherapy or receipt of ≥ 2 prior chemotherapy regimens except
as defined in the Inclusion Criteria

- Known brain metastases

- Prior ixabepilone therapy

- Concurrent active infection requiring antibiotics or other therapy

- Concurrent unstable disease or illness that could jeopardize participation in study

- Impaired cardiac function with LVEF of < 50% as measured by MUGA or ECHO

- Malignancy within last 5 years except non-melanoma skin cancer, carcinoma in situ of
the cervix, or of the breast not treated with chemotherapy

- Grade ≥ 2 neuropathy (sensory or motor)

- Inadequate hematologic, renal and hepatic function